Emmaus Life Sciences Posts 2025 Annual Results
Emmaus Life Sciences Reports Annual Financial Results
TORRANCE, Calif.--(BUSINESS WIRE)--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2025.
Emmaus Life Sciences, a biopharmaceutical company specializing in sickle cell disease treatment, released its 2025 financial results. The OTCQB-listed firm reported on its operational performance and financial condition for the year ending December 31, 2025. The announcement marks the company's latest update on its commercial-stage initiatives.
Explore More
Related News
8 Best Life Sciences Penny Stocks to Buy
Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey · 2026.04.14
Health Sciences Weekend Unites Alumni Around Shared Health Science Center Story - UTHSC News
UTHSC News · 2026.04.14
Molecular Sciences Building - Premier Construction
ROMA Publications Ltd · 2026.04.14
Designing Winners - College of Arts and Sciences
College of Arts and Sciences · 2026.04.14
Universe: Starting from PU, a life in science
News Headlines: Top News Today & Breaking News | Tribune India · 2026.04.13
MAHA and science-based public health: Can’t we all just get along? | Science-Based Medicine
Science-Based Medicine · 2026.04.15